[Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].
Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.
Tada
Atsuhiko
A
Dept. of Internal Medicine, National Minami-Okayama Hospital.
Ueoka
Hiroshi
H
Kiura
Katsuyuki
K
Tabata
Masahiro
M
Takemoto
Mitsuhiro
M
Yamane
Hiromichi
H
Hiyama
Junichiro
J
Aoe
Keisuke
K
Shibayama
Takuo
T
Kamei
Haruhito
H
Kawahara
Shin
S
Harita
Shingo
S
Sato
Toshio
T
Kobayashi
Makoto
M
Eguchi
Kenji
K
Hiraki
Shunkichi
S
Hiraki
Yoshio
Y
Tanimoto
Mitsune
M
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015996:Survival Rate
D005047:Etoposide; D016190:Carboplatin